Device Trial Radar · NCT02963441
A Multi-center Study to Evaluate Performance of an Automated Device for the Detection of Diabetic Retinopathy
Last checked: Nov 19, 2026Latest source record: Mar 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
900
Actual
Start
Jan 2017
Primary completion
Nov 2017
Study completion Dec 2017
Sponsor
- Lead sponsor
- Digital Diagnostics, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 15, 2016
Design
- Study type
- Observational
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Diabetes affects 30.3 million people or 9.3% of the population of the United States. Results of a study by the Eye Diseases Prevalence Research Group reveal that 40% of diabetes patients have some degree of diabetic retinopathy (DR) and that as many as 8% have severe, vision-threatening forms of DR. Early laser photocoagulation in high-risk proliferative diabetic retinopathy (PDR) has been shown to decrease the relative risk of vision loss by as much as 52%. Injections of anti-VEGF agents preserve and improve vision in people with PDR and/or diabetic macular edema. Despite effective treatment however, tens of thousands of people with diabetes are going blind each year largely because they don't undergo annual screening for retinopathy. Currently, less than 50%-60% of people with diabetes have a yearly eye exam and there may not be enough eye specialists to see the balance. The IDx-DR System is intended for use by health care providers to automatically detect more than mild diabetic retinopathy (mtmDR) in adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy. IDx-DR is indicated for use with the Topcon NW400.
Conditions
- Diabetic Retinopathy
Interventions
LumineticsCore (formerly IDX-DR)Device
Prospective analysis on an existing subgroup of subjects in the US pivotal study, version 01 and version 02.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity Corrected for EnrichmentTime frame: Day 1
- Specificity Corrected for EnrichmentTime frame: Day 1
- Observed SensitivityTime frame: Day 1
2 more outcomes with a free account
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.